WuXi Biologics Plant 5 completed the first batch of GMP and successfully produced 24,000 liters of stock solution production line

The 24,000-liter production line follows WuXi Biologics’ unique “horizontal expansion” strategy, which combines 12 2000-liter disposable bioreactors to achieve different scale production, which can flexibly match customers' different cell culture processes such as feeding, perfusion, and CFB.

"MFG5 is one of the world's largest biopharmaceutical stock plants that only use disposable bioreactors, and its cost is comparable to any current traditional stainless steel bioreactor plants with a scale of up to 25,000 liters

About WuXiUP ^TM ultra-efficient continuous production platform

WuXiUP ^TM is an enhanced production technology platform based on continuous perfusion technology, providing a new generation of high-yield, high-quality biopharmaceutical production solutions, while simultaneously having high flexibility and cost-effectiveness

WuXiUP ^TM has successfully empowered more than 40 projects such as monoclonal antibodies, bispecific antibodies, fusion proteins and enzymes, and the cumulative output has increased by an average of 6.

About WuXi Biologics

WuXi Biologics (stock code: 2269.

As of June 30, 2021, 408 comprehensive projects have been developed on WuXi Biologics platform, including 212 in preclinical research phase, 160 in early clinical (phase I/II) phase, and 32 in late clinical phase ( Phase III) and 4 are in the commercial production stage

WuXi Biologics regards environment, society and governance (ESG) as an important part of business development and corporate spirit, and is committed to becoming a global ESG leader in the field of biopharmaceuticals

For more information, please contact

Media Relations

Investor Relations